Semaglutide vs Bariatric Surgery Safety for Obese Patient Weight Management

Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whether the drug is a safer alternative for obese patients.

Alpert, Zoe et al.·The Journal of arthroplasty·2025·Moderate Evidencecohort
RPEP-09899CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=medium
Participants
Patients undergoing total hip arthroplasty who used semaglutide or had prior bariatric surgery

What This Study Found

Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whether the drug is a safer alternative for obese patients.

Key Numbers

Retrospective review of THAs from 2012-2024 comparing semaglutide users versus prior bariatric surgery patients.

How They Did This

Methodology in publication.

Why This Research Matters

Relevant to peptide-based therapeutic applications.

The Bigger Picture

Contributes to peptide therapeutic evidence.

What This Study Doesn't Tell Us

Limitations in publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to evidence?
  • ?Next research?

Trust & Context

Key Stat:
Key finding Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whethe
Evidence Grade:
Based on study design.
Study Age:
Published in 2025.
Original Title:
Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?
Published In:
The Journal of arthroplasty (2025)
Database ID:
RPEP-09899

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Analysis compares semaglutide safety with bariatric surgery for weight management, evaluating whether the drug is a safer alternative for obese patients.

How reliable?

Consult publication and provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09899·https://rethinkpeptides.com/research/RPEP-09899

APA

Alpert, Zoe; Katzman, Jonathan L; Lajam, Claudette M; Schwarzkopf, Ran; Rozell, Joshua C. (2025). Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?. The Journal of arthroplasty. https://doi.org/10.1016/j.arth.2025.08.068

MLA

Alpert, Zoe, et al. "Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?." The Journal of arthroplasty, 2025. https://doi.org/10.1016/j.arth.2025.08.068

RethinkPeptides

RethinkPeptides Research Database. "Is Semaglutide a Safer Weight-Management Option Than Bariatr..." RPEP-09899. Retrieved from https://rethinkpeptides.com/research/alpert-2025-is-semaglutide-a-safer

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.